Literature DB >> 15681456

Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development.

Anjan Purkayastha1, Susan E Ditty, Jing Su, John McGraw, Ted L Hadfield, Clark Tibbetts, Donald Seto.   

Abstract

Human adenovirus serotype 4 (HAdV-4) is a reemerging viral pathogenic agent implicated in epidemic outbreaks of acute respiratory disease (ARD). This report presents a genomic and bioinformatics analysis of the prototype 35,990-nucleotide genome (GenBank accession no. AY594253). Intriguingly, the genome analysis suggests a closer phylogenetic relationship with the chimpanzee adenoviruses (simian adenoviruses) rather than with other human adenoviruses, suggesting a recent origin of HAdV-4, and therefore species E, through a zoonotic event from chimpanzees to humans. Bioinformatics analysis also suggests a pre-zoonotic recombination event, as well, between species B-like and species C-like simian adenoviruses. These observations may have implications for the current interest in using chimpanzee adenoviruses in the development of vectors for human gene therapy and for DNA-based vaccines. Also, the reemergence, surveillance, and treatment of HAdV-4 as an ARD pathogen is an opportunity to demonstrate the use of genome determination as a tool for viral infectious disease characterization and epidemic outbreak surveillance: for example, rapid and accurate low-pass sequencing and analysis of the genome. In particular, this approach allows the rapid identification and development of unique probes for the differentiation of family, species, serotype, and strain (e.g., pathogen genome signatures) for monitoring epidemic outbreaks of ARD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681456      PMCID: PMC546560          DOI: 10.1128/JVI.79.4.2559-2572.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  90 in total

1.  Fatal pneumonia associated with adenovirus type 7 in three military trainees.

Authors:  B A Dudding; S C Wagner; J A Zeller; J T Gmelich; G R French; F H Top
Journal:  N Engl J Med       Date:  1972-06-15       Impact factor: 91.245

2.  Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants.

Authors:  M Basnight; N G Rogers; C J Gibbs; D C Gajdusek
Journal:  Am J Epidemiol       Date:  1971-08       Impact factor: 4.897

3.  Genetic studies with tumorigenic adenoviruses. 3. Recombination in adenovirus type 12.

Authors:  N Takemori
Journal:  Virology       Date:  1972-01       Impact factor: 3.616

4.  Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.

Authors:  T J Wickham; P Mathias; D A Cheresh; G R Nemerow
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

5.  Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families.

Authors:  A R Shaw; E B Ziff
Journal:  Cell       Date:  1980-12       Impact factor: 41.582

6.  Characterization of two temperature-sensitive mutants of type 5 adenovirus with mutations in the 100,000-dalton protein gene.

Authors:  E A Oosterom-Dragon; H S Ginsberg
Journal:  J Virol       Date:  1981-11       Impact factor: 5.103

7.  Further studies of the viruses of the chimpanzee I. Viral infection of colony-maintained chimpanzees.

Authors:  K F Soike; F Coulston; J D Douglas
Journal:  Exp Mol Pathol       Date:  1969-12       Impact factor: 3.362

8.  Genome analysis of adenovirus 4 isolated over a six year period.

Authors:  R J Cooper; A S Bailey; R Killough; S J Richmond
Journal:  J Med Virol       Date:  1993-01       Impact factor: 2.327

9.  Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.

Authors:  F H Top; E L Buescher; W H Bancroft; P K Russell
Journal:  J Infect Dis       Date:  1971-08       Impact factor: 5.226

10.  Adeno-viral kerato conjunctivitis.

Authors:  R M Stasiuk; I F Robertson
Journal:  Aust J Ophthalmol       Date:  1981-02
View more
  32 in total

1.  Complete genome sequence of human adenovirus prototype 17.

Authors:  Shoaleh Dehghan; Jason Seto; Nolan R Hudson; Christopher M Robinson; Morris S Jones; David W Dyer; James Chodosh; Donald Seto
Journal:  J Virol       Date:  2011-11       Impact factor: 5.103

2.  Novel adenoviruses in wild primates: a high level of genetic diversity and evidence of zoonotic transmissions.

Authors:  Diana Wevers; Sonja Metzger; Fred Babweteera; Marc Bieberbach; Christophe Boesch; Kenneth Cameron; Emmanuel Couacy-Hymann; Mike Cranfield; Maryke Gray; Laurie A Harris; Josephine Head; Kathryn Jeffery; Sascha Knauf; Felix Lankester; Siv Aina J Leendertz; Elizabeth Lonsdorf; Lawrence Mugisha; Andreas Nitsche; Patricia Reed; Martha Robbins; Dominic A Travis; Zinta Zommers; Fabian H Leendertz; Bernhard Ehlers
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy.

Authors:  Ijad Madisch; Gabi Harste; Heidi Pommer; Albert Heim
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.

Authors:  Ijad Madisch; Soeren Hofmayer; Christian Moritz; Alexander Grintzalis; Jens Hainmueller; Patricia Pring-Akerblom; Albert Heim
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

5.  Simian adenovirus type 35 has a recombinant genome comprising human and simian adenovirus sequences, which predicts its potential emergence as a human respiratory pathogen.

Authors:  Shoaleh Dehghan; Jason Seto; Morris S Jones; David W Dyer; James Chodosh; Donald Seto
Journal:  Virology       Date:  2013-10-08       Impact factor: 3.616

6.  Genomic characterization of human adenovirus type 4 strains isolated worldwide since 1953 identifies two separable phylogroups evolving at different rates from their most recent common ancestor.

Authors:  Gabriel Gonzalez; Camden R Bair; Daryl M Lamson; Hidemi Watanabe; Laura Panto; Michael J Carr; Adriana E Kajon
Journal:  Virology       Date:  2019-09-08       Impact factor: 3.616

7.  Genomic and bioinformatics analyses of HAdV-4vac and HAdV-7vac, two human adenovirus (HAdV) strains that constituted original prophylaxis against HAdV-related acute respiratory disease, a reemerging epidemic disease.

Authors:  Anjan Purkayastha; Jing Su; John McGraw; Susan E Ditty; Ted L Hadfield; Jason Seto; Kevin L Russell; Clark Tibbetts; Donald Seto
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

8.  Multiple Cross-Species Transmission Events of Human Adenoviruses (HAdV) during Hominine Evolution.

Authors:  Eileen Hoppe; Maude Pauly; Thomas R Gillespie; Chantal Akoua-Koffi; Gottfried Hohmann; Barbara Fruth; Stomy Karhemere; Nadège F Madinda; Lawrence Mugisha; Jean-Jacques Muyembe; Angelique Todd; Klara J Petrzelkova; Maryke Gray; Martha Robbins; Richard A Bergl; Roman M Wittig; Klaus Zuberbühler; Christophe Boesch; Grit Schubert; Fabian H Leendertz; Bernhard Ehlers; Sébastien Calvignac-Spencer
Journal:  Mol Biol Evol       Date:  2015-04-09       Impact factor: 16.240

9.  Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis.

Authors:  Michael P Walsh; Ashish Chintakuntlawar; Christopher M Robinson; Ijad Madisch; Balázs Harrach; Nolan R Hudson; David Schnurr; Albert Heim; James Chodosh; Donald Seto; Morris S Jones
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

10.  Unique sequence features of the Human adenovirus 31 complete genomic sequence are conserved in clinical isolates.

Authors:  Soeren Hofmayer; Ijad Madisch; Sebastian Darr; Fabienne Rehren; Albert Heim
Journal:  BMC Genomics       Date:  2009-11-25       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.